• X-Gal Workflow for Cloning and β-Galactosidase Assays

  2026-09-10

  Build more reliable blue-white colony screening with a practical X-Gal workflow covering stock preparation, plate formulation, controls, and colony interpretation. The same chromogenic readout can also support lacZ reporter development, while the iRhom2 olfaction study shows where this assay is useful as an orthogonal tool rather than a substitute for molecular signaling measurements.

• EPZ5676: DOT1L Inhibition Beyond Leukemia

  2026-09-09

  EPZ5676 is a highly selective DOT1L inhibitor for dissecting H3K79 methylation in leukemia and renal fibrosis models. This article focuses on assay interpretation, cross-domain evidence, and experimental decisions that distinguish target engagement from nonspecific cytotoxicity.

• VE-822: ATR Inhibitor for DDR Research

  2026-09-09

  VE-822 is a potent and selective ATR inhibitor with a reported biochemical IC50 of 0.019 μM. Its research value centers on DNA damage response inhibition and the study of pancreatic cancer sensitization to radiation and gemcitabine.

• 5-hme-dCTP: From Reagent to Assay Design

  2026-09-08

  5-hme-dCTP is more than a modified nucleotide triphosphate: it can help build controlled substrates, interrogate polymerase behavior, and strengthen 5hmC assay interpretation. This guide connects reagent selection with rice drought-response epigenetics while defining practical limits and controls.

• Tetrahydromagnolol in CB2 Signaling Workflows

  2026-09-08

  Tetrahydromagnolol supports selective peripheral CB2 receptor activation studies while offering a built-in GPR55 antagonist counterpoint. This article shows how to connect receptor pharmacology with inflammation, analgesic mechanism, and exploratory cytoskeletal assays without overstating what is known about cross-pathway signaling.

• Dual SMAD and Wnt Inhibition for iPSC-RGC Differentiation

  2026-09-07

  Chavali and colleagues developed a chemically defined, non-genetic method that combines dual SMAD and canonical Wnt inhibition to direct human induced pluripotent stem cells toward retinal ganglion cells. The protocol improved yield and reproducibility, producing cultures with more than 80% RGC purity and enabling additional Thy-1-positive enrichment to nearly 95%, supporting robust in vitro models of glaucoma and optic neurodegeneration.

• Trichostatin A (TSA) for Epigenetic Workflows

  2026-09-07

  Trichostatin A (TSA) provides a reversible way to connect HDAC activity with histone acetylation, cell-cycle control, differentiation, and cancer phenotypes. This practical guide covers concentration planning, assay controls, senescence-informed interpretation, and troubleshooting for reproducible cell and translational workflows.

• TCAIM Reprograms Mitochondrial OGDH Proteostasis

  2026-09-05

  A 2025 Molecular Cell study identifies TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The work establishes mitochondrial proteostasis as a post-translational mechanism for tuning α-ketoglutarate dehydrogenase activity and carbohydrate metabolism.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-04

  Borchert et al. integrated drug-response experiments with homologous recombination repair gene-expression profiling to examine whether BRCAness identifies malignant pleural mesothelioma models susceptible to olaparib. Their findings support biomarker-guided PARP inhibition, particularly in BAP1-mutated cells, while emphasizing that the proposed treatment combinations require clinical validation.

• Tranexamic Acid for Fibrinolysis Workflows

  2026-09-04

  Tranexamic Acid gives fibrinolysis research a practical way to connect plasmin inhibition with clot-stability, cell-adhesion, and biomaterial assays. This workflow translates a 2024 TXA–NO–propolis dressing study into controlled experiments while separating antifibrinolytic activity from antibacterial and material effects.

• Rhodamine B Workflows for Imaging and Tracing

  2026-09-03

  Rhodamine B combines aqueous and organic-solvent compatibility with a practical red-fluorescence readout for cell labeling, microscopy, assay calibration, and tracer studies. This guide turns the reagent into reproducible workflows while showing how its signal can support, but not replace, mechanistic validation in responsive nanomedicine.

• How to Measure Cancer Drug Responses In Vitro

  2026-09-03

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. By separating proliferative arrest from cell killing and considering their different proportions and timing, the work provides a more precise framework for interpreting in vitro drug-response experiments.

• 3-Deazaadenosine: SAH Hydrolase Inhibitor

  2026-09-02

  3-Deazaadenosine is a S-adenosylhomocysteine hydrolase inhibitor that raises intracellular SAH and suppresses SAM-dependent methyltransferase activity. Its documented antiviral profile against Ebola and Marburg viruses supports preclinical antiviral research, while its methylation mechanism provides a tool for studying epigenetic and infection-related pathways.

• SGI-1027 and Everolimus in Renal Cancer

  2026-09-02

  This 2024 Advanced Science study identifies SGI-1027 as an inducer of methuosis and shows that it cooperates with everolimus to suppress renal cancer growth, migration, and invasion. The combination links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a mechanistic framework for addressing limitations of everolimus treatment.

• Amyloid Beta-Peptide (1-40) Assay Logic

  2026-09-01

  Amyloid Beta-Peptide (1-40) (human) is a sequence-defined model for connecting peptide state, membrane context, calcium exposure, and Alzheimer’s disease mechanisms. This article converts recent surface-sensitive aggregation findings into practical decisions for reproducible assays.

7969 records 1/532 page Next 12345 下5页 Last page